A citation-based method for searching scientific literature

K A Papp, C E M Griffiths, K Gordon, M Lebwohl, P O Szapary, Y Wasfi, D Chan, M-C Hsu, V Ho, P D Ghislain, B Strober, K Reich. Br J Dermatol 2013
Times Cited: 285







List of co-cited articles
1626 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
31

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao,[...]. N Engl J Med 2016
850
29

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li,[...]. Lancet 2008
26

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
487
22

Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kim Papp, Alice B Gottlieb, Luigi Naldi, David Pariser, Vincent Ho, Kavitha Goyal, Steven Fakharzadeh, Marc Chevrier, Stephen Calabro, Wayne Langholff,[...]. J Drugs Dermatol 2015
204
21

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
K A Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, R G Langley, J Cather, A B Gottlieb,[...]. Br J Dermatol 2016
281
19

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
466
18

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Christopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, Bei Zhou, Shu Li,[...]. N Engl J Med 2010
620
18

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
David Fiorentino, Vincent Ho, Mark G Lebwohl, Luiz Leite, Lori Hopkins, Claudia Galindo, Kavitha Goyal, Wayne Langholff, Steven Fakharzadeh, Bhaskar Srivastava,[...]. J Am Acad Dermatol 2017
83
20

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
16



Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
958
14


Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
Peter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, Craig L Leonardi, Andrew Blauvelt, Tsen-Fang Tsai, Yankun Gong, Jiaqing Huang, Charis Papavassilis, Todd Fox. J Am Acad Dermatol 2016
191
14


Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
264
14

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
303
13

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
A B Kimball, K A Papp, Y Wasfi, D Chan, R Bissonnette, H Sofen, N Yeilding, S Li, P Szapary, K B Gordon. J Eur Acad Dermatol Venereol 2013
128
13

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
516
13

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
280
13

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
W J Sandborn, P Rutgeerts, C Gasink, D Jacobstein, B Zou, J Johanns, B E Sands, S B Hanauer, S Targan, S Ghosh,[...]. Aliment Pharmacol Ther 2018
77
16

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring,[...]. N Engl J Med 2017
288
12

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
William J Sandborn, Christopher Gasink, Long-Long Gao, Marion A Blank, Jewel Johanns, Cynthia Guzzo, Bruce E Sands, Stephen B Hanauer, Stephan Targan, Paul Rutgeerts,[...]. N Engl J Med 2012
739
12

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan,[...]. N Engl J Med 2015
482
11


Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
549
11

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
Mark Lebwohl, Craig Leonardi, Christopher E M Griffiths, Jörg C Prinz, Philippe O Szapary, Newman Yeilding, Cynthia Guzzo, Shu Li, Ming-Chun Hsu, Bruce Strober. J Am Acad Dermatol 2012
79
13

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Bruce Strober, Craig Leonardi, Kim A Papp, Ulrich Mrowietz, Mamitaro Ohtsuki, Robert Bissonnette, Laura K Ferris, Carle Paul, Mark Lebwohl, Daniel K Braun,[...]. J Am Acad Dermatol 2017
76
14

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
357
11

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Alice Gottlieb, Alan Menter, Alan Mendelsohn, Yaung-Kaung Shen, Shu Li, Cynthia Guzzo, Scott Fretzin, Rod Kunynetz, Arthur Kavanaugh. Lancet 2009
431
11

Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
O Ahlehoff, L Skov, G Gislason, R Gniadecki, L Iversen, L E Bryld, S Lasthein, J Lindhardsen, S L Kristensen, C Torp-Pedersen,[...]. J Eur Acad Dermatol Venereol 2015
126
11

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
801
11

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
Stephan R Targan, Brian Feagan, Severine Vermeire, Remo Panaccione, Gil Y Melmed, Carol Landers, Dalin Li, Chris Russell, Richard Newmark, Nan Zhang,[...]. Am J Gastroenterol 2016
206
11

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
J-H Saurat, G Stingl, L Dubertret, K Papp, R G Langley, J-P Ortonne, K Unnebrink, M Kaul, A Camez. Br J Dermatol 2008
528
10

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
522
10

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
218
10

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Gerald G Krueger, Richard G Langley, Craig Leonardi, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Lisa T Dooley, Mark Lebwohl. N Engl J Med 2007
592
10


Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Alan Menter, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, Martin Kaul, Yihua Gu, Martin Okun,[...]. J Am Acad Dermatol 2008
629
10

The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
Erica D Dommasch, Katrina Abuabara, Daniel B Shin, Josephine Nguyen, Andrea B Troxel, Joel M Gelfand. J Am Acad Dermatol 2011
162
10

Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies.
C Pouplard, E Brenaut, C Horreau, T Barnetche, L Misery, M-A Richard, S Aractingi, F Aubin, B Cribier, P Joly,[...]. J Eur Acad Dermatol Venereol 2013
130
10

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
K Papp, D Thaçi, K Reich, E Riedl, R G Langley, J G Krueger, A B Gottlieb, H Nakagawa, E P Bowman, A Mehta,[...]. Br J Dermatol 2015
183
10

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Kenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C Prinz, Yasmine Wasfi, Shu Li, Yaung-Kaung Shen, Philippe Szapary, Bruce Randazzo, Kristian Reich. N Engl J Med 2015
206
10

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
Tsen-Fang Tsai, Ji-Chen Ho, Michael Song, Philippe Szapary, Cynthia Guzzo, Yuang-Kuang Shen, Shu Li, Kwang-Joong Kim, Tae-Yoon Kim, Jee-Ho Choi,[...]. J Dermatol Sci 2011
148
10

Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
Rosa Parisi, Deborah P M Symmons, Christopher E M Griffiths, Darren M Ashcroft. J Invest Dermatol 2013
10


Risk of cancer in patients with psoriasis on biological therapies: a systematic review.
E Peleva, L S Exton, K Kelley, C E Kleyn, K J Mason, C H Smith. Br J Dermatol 2018
54
18

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Brian G Feagan, William J Sandborn, Geert D'Haens, Julián Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Denis Franchimont, Olivier Dewit, Ursula Seidler,[...]. Lancet 2017
259
9

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
K A Papp, R G Langley, B Sigurgeirsson, M Abe, D R Baker, P Konno, S Haemmerle, H J Thurston, C Papavassilis, H B Richards. Br J Dermatol 2013
271
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.